{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T04:48:13Z","timestamp":1750481293377},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.dld.2009.10.006","type":"journal-article","created":{"date-parts":[[2009,12,17]],"date-time":"2009-12-17T15:11:11Z","timestamp":1261062671000},"page":"496-502","source":"Crossref","is-referenced-by-count":14,"title":["No beneficial effects of amantadine in treatment of chronic hepatitis C patients"],"prefix":"10.1016","volume":"42","author":[{"given":"Hanneke","family":"van Soest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"van der Schaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ger H.","family":"Koek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy A.","family":"van Ooteghem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan M.","family":"Vrolijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob J.","family":"Lieverse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Houben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annet","family":"van der Sluys Veer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Siersema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marguerite E.I.","family":"Schipper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greet J.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2009.10.006_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2009.10.006_bib2","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2009.10.006_bib3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2009.10.006_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM198209023071002","article-title":"A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection","volume":"307","author":"Dolin","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2009.10.006_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1128\/AAC.18.1.125","article-title":"Inhibition of dengue virus replication by amantadine hydrochloride","volume":"18","author":"Koff","year":"1980","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dld.2009.10.006_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0166-3542(89)90018-1","article-title":"Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A","volume":"11","author":"Reuman","year":"1989","journal-title":"Antiviral Res"},{"key":"10.1016\/j.dld.2009.10.006_bib7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jama.245.11.1128","article-title":"Successful treatment of naturally occurring influenza A\/USSR\/77 H1N1","volume":"245","author":"Van Voris","year":"1981","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.dld.2009.10.006_bib8","first-page":"611","article-title":"Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients","volume":"30","author":"Tabone","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0168-8278(01)00140-4","article-title":"Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study","volume":"35","author":"Caronia","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jhep.2003.11.002","article-title":"Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials","volume":"40","author":"Mangia","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib11","first-page":"130","article-title":"Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders","volume":"31","author":"Brillanti","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1023\/A:1018857314351","article-title":"Treatment of chronic hepatitis C with amantadine","volume":"42","author":"Smith","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.dld.2009.10.006_bib13","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1053\/jhep.2003.50219","article-title":"Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial","volume":"37","author":"Berg","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2009.10.006_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/jhep.2002.31168","article-title":"Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial","volume":"35","author":"Helbling","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2009.10.006_bib15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1053\/jhep.2001.23537","article-title":"A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C","volume":"33","author":"Mangia","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2009.10.006_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0168-8278(01)00166-0","article-title":"Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients","volume":"35","author":"Tabone","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.21686","article-title":"Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus","volume":"46","author":"Steinmann","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2009.10.006_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/j.gastro.2005.11.010","article-title":"American Gastroenterological Association technical review on the management of hepatitis C","volume":"130","author":"Dienstag","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2009.10.006_bib19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2893.2005.00591.x","article-title":"A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs. interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C","volume":"12","author":"Mangia","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.dld.2009.10.006_bib20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/MEG.0b013e3282f5196c","volume":"20","author":"Angelico","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib21","first-page":"S1342","article-title":"Randomized, double-blind, placebo-controlled trial of Peginterferon alfa-2a (40kD) and ribavirin with and without 400mg amantadine-sulphate for 48 weeks in treatment naive HCV genotype 1-infected patients","volume":"46","author":"von Wagner","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2009.10.006_bib22","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2004.05.019","article-title":"Evaluation of amantadine in chronic hepatitis C: a meta-analysis","volume":"41","author":"Deltenre","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0168-8278(03)00298-8","article-title":"Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C","volume":"39","author":"Teuber","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jhep.2004.07.019","article-title":"Induction therapy in chronic hepatitis C: deja-vu with pegylated interferons?","volume":"41","author":"Zeuzem","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.dld.2009.10.006_bib26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2009.10.006_bib27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1440-1746.2003.03256.x","article-title":"Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection","volume":"19","author":"Silva","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2009.10.006_bib28","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865809004307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865809004307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T13:20:58Z","timestamp":1544793658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865809004307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S1590865809004307"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2009.10.006","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}